Privi Speciality Chemicals reported a 22.7% year-on-year increase in standalone net profit to ₹84.26 crore for the quarter ended June 30, 2026, driven by higher revenue from operations. The company’s consolidated net profit attributable to owners of the holding company rose 35.8% YoY to ₹84.21 crore, reflecting strong performance in its single operating segment, Aroma Chemical. Revenue from operations increased 6.0% YoY on a standalone basis to ₹60.06 crore and surged 19.2% YoY on a consolidated basis to ₹66.62 crore.

The Board of Directors approved the unaudited financial results at its meeting held on July 30, 2026, pursuant to Regulation 30 read with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the statutory auditors, B S R & Co. LLP, who issued an unmodified limited review report. The figures for the quarter ended March 31, 2026, are balancing figures between audited full-year results and published nine-month figures.

Financial Performance Highlights

Standalone other income increased significantly to ₹14.62 crore from ₹8.31 crore in the corresponding quarter last year, contributing to total income growth. On a consolidated basis, other income rose to ₹15.20 crore from ₹8.99 crore YoY. Total expenses stood at ₹50.22 crore on a standalone basis and ₹56.81 crore on a consolidated basis.

What the Numbers Show

The divergence between standalone and consolidated revenue growth highlights the impact of subsidiaries on overall top-line performance. While standalone revenue grew modestly by 6.0%, consolidated revenue expanded by 19.2%, indicating robust contribution from group entities such as Privi Biotechnologies Private Limited and Privi Speciality Chemicals USA Corporation. This suggests that international or subsidiary operations are currently driving the primary volume growth for the group.

Cost management remained effective, with finance costs declining both standalone (from ₹19.67 crore to ₹13.21 crore) and consolidated (from ₹23.66 crore to ₹16.74 crore) compared to the previous year’s quarter. However, cost of materials consumed increased in line with revenue growth, rising 25.2% standalone and 29.8% consolidated, reflecting input cost pressures or mix shifts in the aroma chemical segment.

Corporate Developments

The Board had previously recommended a final dividend of ₹10 per equity share for the financial year ended March 31, 2026, aggregating to ₹39.06 crore, subject to shareholder approval at the 41st annual general meeting. Additionally, the Scheme of Amalgamation of Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited with the parent company was filed before the National Company Law Tribunal (NCLT), Mumbai Bench, on June 25, 2026, following observation letters from NSE and BSE.

Privi Speciality Chemicals delivered a notable improvement in its consolidated financial performance for Q1, with net profit rising to 842M rupees compared to 619M rupees in the corresponding quarter of the previous year. The company also reported healthy revenue growth, with top-line figures climbing to 6.66B rupees from 5.6B rupees on a year-on-year basis, underscoring broad-based business momentum.

Q1 Financial Performance at a Glance

The quarterly results reflect growth across key financial metrics. The table below summarises the company's performance compared to the year-ago period:

Revenue and Profitability

Privi Speciality Chemicals' revenue for Q1 grew to 6.66B rupees from 5.6B rupees in the year-ago quarter, reflecting a meaningful expansion in the company's top line. Net profit for the period came in at 842M rupees, up from 619M rupees recorded in the same quarter last year, demonstrating improved bottom-line performance on a year-on-year basis.

EBITDA and Margin Trends

The company's EBITDA for Q1 stood at 1.52B rupees, compared to 1.32B rupees in the corresponding period of the previous year, indicating growth in operating earnings. However, the EBITDA margin for the quarter was recorded at 22.86%, a slight contraction from 23.63% reported in the year-ago period. The marginal decline in EBITDA margin, despite absolute EBITDA growth, suggests that revenue expansion outpaced operating profit growth during the quarter.